In this study, we show that FGF10/FGFR2-signalling has an important role in pancreatic cancer progression, and we suggest that these results may lead to a new therapy and a better prognosis for patients with pancreatic cancer. This evidence concerns the gene FGF10 and familial pancreatic carcinoma.